Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

OBJECTIVE: To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany. METHODS: Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA) is a non-interventional real-world study to prospectively assess the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Lang, Michael, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Lang, Stefan, Winkelmann, Veronika E., Ettle, Benjamin, Schulze-Topphoff, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120082/
https://www.ncbi.nlm.nih.gov/pubmed/34982201
http://dx.doi.org/10.1007/s00415-021-10931-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120082/
https://www.ncbi.nlm.nih.gov/pubmed/34982201
http://dx.doi.org/10.1007/s00415-021-10931-w

Ejemplares similares